Related Experiment Videos
Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA
G J Blauw1, A M Lagaay, A H Smelt
1Department of General Internal Medicine, Leiden University Medical Centre, Netherlands.
Insights
Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, significantly reduce stroke risk by 31% in middle-aged individuals. These findings highlight the importance of statin therapy for stroke prevention.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Stroke is a leading cause of disability and mortality.
- 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are widely used to lower cholesterol levels.
- The impact of statins on stroke risk requires comprehensive evaluation.
Purpose of the Study:
- To estimate the effect of HMG-CoA reductase inhibitors (statins) on stroke risk.
- To synthesize data from randomized, placebo-controlled, double-blind trials of statins.
Main Methods:
- Systematic literature search of Medline CD+ and Current Contents (1980-1996).
- Inclusion criteria: placebo-controlled, double-blind trials of statin monotherapy.
- Statistical analysis comparing observed strokes with expected strokes under the null hypothesis.
Main Results:
- Analyzed 13 trials with 20,438 participants and 462 strokes.
- 181 strokes in statin groups vs. 261 in placebo groups.
- Statins demonstrated a 31% reduction in stroke risk (OR, 0.69; 95% CI, 0.57-0.83).
Conclusions:
- HMG-CoA reductase inhibitors (statins) are effective in preventing stroke in middle-aged populations.
- The findings support the use of statins for stroke prevention.
- Further trials are warranted to assess statin efficacy in elderly populations, where stroke incidence is higher.
Background And Purpose:
To estimate the effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors ("statins") on stroke ris, we combined the data of the randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors published so far.
Methods:
The studies were identified using the Medline CD+ and Current Contents databases from January 1980 through May 1996, inclusive. All studies were evaluated on the use of a placebo control, monotherapy, and double blindness. When the type of stroke or the occurrence of clinical events or adverse effects were incompletely or not reported, the investigators were contacted personally. For each trial, the number of strokes in the treatment arm was compared with the number of strokes expected on all observations under the assumption that drug treatment had no effect.
Results:
A total of 462 strokes among 20438 participants in 13 trials could be analyzed. A total of 181 strokes were observed in patients randomized to treatment with an HMG-CoA reductase inhibitor and 261 strokes in patients randomized to placebo. A lower than expected number of strokes was observed in the treatment groups of all but one trial (P = .001). Treatment with an HMG-CoA reductase inhibitor led to an overall risk reduction of 31% (odds ratio, 0.69; 95% confidence interval, 0.57 to 0.83).
Conclusions:
The combined data suggest that treatment with HMG-CoA reductase inhibitors prevents stroke in middle-aged persons. Because stroke is especially common in older age, these data reinforce the need for clinical trials to evaluate the effect of HMG-CoA reductase inhibitors in preventing stroke in the elderly.